Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride

This article was originally published in The Pink Sheet Daily

Executive Summary

Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.

Advertisement

Related Content

Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners: An Interview With PharmAsia News
Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News (Part 1 of 2)
Lilly and Merck Lead the Way With Asian FIPNet Strategies
India's Nicholas Piramal Signs Second Potential $100 Million R&D Deal with Lilly

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073293

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel